Avalo Therapeutics, Inc.
AVTX
$19.94
-$0.31-1.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 55.20% | -47.48% | -57.92% | 62.79% | -253.40% |
| Total Depreciation and Amortization | -72.88% | -55.97% | -0.74% | 98.53% | 100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -104.68% | 172.74% | 138.43% | -88.68% | 162.97% |
| Change in Net Operating Assets | 115.36% | -131.71% | 201.92% | 295.59% | 59.39% |
| Cash from Operations | 12.95% | -43.68% | -20.44% | 37.14% | -30.51% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 118.11% | 81.29% | -- | -- | -- |
| Cash from Investing | 118.11% | 81.29% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -92.00% | 35,825.00% | -- | -- | -- |
| Repurchase of Common Stock | 100.00% | 99.80% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -95.22% | 3,163.75% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.87% | 81.56% | -774.69% | -117.96% | 556.88% |